Conference Coverage

Weight-Loss Drug Hits Diabetes Target Trifecta

Publish date: July 12, 2012

 

AT THE ANNUAL MEETING OF THE ENDOCRINE SOCIETY

Dr. Ryan reported serving as a scientific advisor to Vivus but holds no equity interest in the company.

Pages

Recommended Reading

Hydroxychloroquine Cuts Diabetes Risk in Rheumatoid Arthritis
MDedge Internal Medicine
Metformin May Reduce Liver Cancer Risk
MDedge Internal Medicine
PSA May Be Unreliable in Type 1 Diabetes
MDedge Internal Medicine
Despite Cardiac Concerns, FDA OKs Obesity Drug Lorcaserin
MDedge Internal Medicine
GSK Pays $3 Billion to Settle Drug Promotion Charges
MDedge Internal Medicine
Post-MI Rehospitalization Rate Has Not Declined Since 1987
MDedge Internal Medicine
Tracking System Proposed for Medical Devices
MDedge Internal Medicine
Type 2 Diabetes Re-Emerges After Bariatric Surgery
MDedge Internal Medicine
Bariatric Surgery Yields Durable Results for Diabetic Nephropathy
MDedge Internal Medicine
Newer Technologies May Improve Diabetes Control
MDedge Internal Medicine